| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Ian MacLachlan | |
| Adam Judge | |||
| P433 | issue | 2 | |
| P304 | page(s) | 111-124 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Human Gene Therapy | Q15757580 |
| P1476 | title | Overcoming the innate immune response to small interfering RNA. | |
| P478 | volume | 19 |
| Q42270700 | A novel 4-arm DNA/RNA Nanoconstruct triggering Rapid Apoptosis of Triple Negative Breast Cancer Cells within 24 hours |
| Q31012608 | A simple Bayesian estimate of direct RNAi gene regulation events from differential gene expression profiles |
| Q35204876 | AAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i. |
| Q46543595 | Acidic pH-responsive siRNA conjugate for reversible carrier stability and accelerated endosomal escape with reduced IFNα-associated immune response. |
| Q24624648 | Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter |
| Q40390793 | Adenosine modification may be preferred for reducing siRNA immune stimulation |
| Q45883115 | Adenovirus in a synthetic membrane wrapper: an example of hybrid vigor? |
| Q38706445 | Advances in the delivery of RNA therapeutics: from concept to clinical reality. |
| Q47217912 | Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer |
| Q38227931 | An update on RNA interference-mediated gene silencing in cancer therapy |
| Q35750040 | Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals |
| Q35112225 | Base modification strategies to modulate immune stimulation by an siRNA. |
| Q36460487 | Buffering capacity and size of siRNA polyplexes influence cytokine levels |
| Q81985022 | Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides |
| Q38162098 | Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology |
| Q37655882 | Chemical modification of siRNA. |
| Q34942127 | Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis |
| Q33869361 | Clinical status of duplex RNA |
| Q39463221 | Comparison of polymeric siRNA nanocarriers in a murine LPS-activated macrophage cell line: gene silencing, toxicity and off-target gene expression |
| Q37111373 | Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice |
| Q39196891 | Controllable inhibition of hepatitis B virus replication by a DR1-targeting short hairpin RNA (shRNA) expressed from a DOX-inducible lentiviral vector |
| Q28383550 | Cytokines as biomarkers of nanoparticle immunotoxicity |
| Q38378692 | DNA enzymes as potential therapeutics: towards clinical application of 10-23 DNAzymes. |
| Q34756913 | Deficiency in either 4E-BP1 or 4E-BP2 augments innate antiviral immune responses |
| Q33954008 | Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. |
| Q38160246 | Delivery of RNAi therapeutics: work in progress |
| Q34946937 | Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo |
| Q89910193 | Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA |
| Q24616751 | Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics |
| Q34080079 | Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters |
| Q90126734 | Effect of the Ratio of Betamethasone to TNF-α siRNA Coencapsulated in Solid Lipid Nanoparticles on the Acute Proinflammatory Activity of the Nanoparticles |
| Q33572902 | Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs |
| Q39197452 | Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform |
| Q38236693 | Enhancing siRNA delivery by employing lipid nanoparticles |
| Q43172717 | Gene silencing below the immune radar |
| Q37182756 | Gene therapy progress and prospects: synthetic polymer-based systems. |
| Q39968075 | Global gene expression profiling in cultured cells is strongly influenced by treatment with siRNA-cationic liposome complexes |
| Q37408421 | Identification of RNase L-dependent, 3'-end-modified, viral small RNAs in Sindbis virus-infected mammalian cells |
| Q35635763 | In vivo sustained release of siRNA from solid lipid nanoparticles |
| Q46118467 | Induction of RNAi Responses by Short Left-Handed Hairpin RNAi Triggers |
| Q37714008 | Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy. |
| Q48147273 | Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. |
| Q34736652 | Innovative strategy for microRNA delivery in human mesenchymal stem cells via magnetic nanoparticles |
| Q39704107 | Knockdown of Efp by DNA-modified small interfering RNA inhibits breast cancer cell proliferation and in vivo tumor growth. |
| Q36594145 | Lack of correlation between predicted and actual off-target effects of short-interfering RNAs targeting the human papillomavirus type 16 E7 oncogene |
| Q38148784 | Lentiviral vector-mediated RNA silencing in the central nervous system. |
| Q38463583 | Lentiviral vectors encoding short hairpin RNAs efficiently transduce and knockdown LINGO-1 but induce an interferon response and cytotoxicity in central nervous system neurones. |
| Q37855818 | Leveraging therapeutic potential of multi-targeted siRNA inhibitors |
| Q38172634 | Lipid-based nanoparticles in the systemic delivery of siRNA. |
| Q37425606 | Lipid-based systemic delivery of siRNA. |
| Q36915116 | Liposome delivery of microRNA-145 to mesenchymal stem cells leads to immunological off-target effects mediated by RIG-I. |
| Q38784475 | Magnetic Nanoparticle Based Nonviral MicroRNA Delivery into Freshly Isolated CD105(+) hMSCs |
| Q37213586 | Maintaining the silence: reflections on long-term RNAi |
| Q33393397 | Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses |
| Q39014580 | MicroRNA-targeted therapeutics for lung cancer treatment |
| Q28829013 | MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy |
| Q38956337 | Microporation is an efficient method for siRNA-induced knockdown of PEX5 in HepG2 cells: evaluation of the transfection efficiency, the PEX5 mRNA and protein levels and induction of peroxisomal deficiency |
| Q33637385 | Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice |
| Q33572896 | Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity |
| Q50568503 | Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. |
| Q34622662 | Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances |
| Q38874499 | Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy |
| Q37879444 | New short interfering RNA-based therapies for glomerulonephritis |
| Q91841698 | Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis |
| Q33791247 | Oligonucleotide-based strategies to combat polyglutamine diseases |
| Q39918666 | Permanent silencing of NKG2A expression for cell-based therapeutics |
| Q37873825 | Personalized cancer approach: using RNA interference technology |
| Q88312677 | Potentiating tumor immunity using aptamer-targeted RNAi to render CD8+ T cells resistant to TGFβ inhibition |
| Q33752590 | Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing |
| Q28255877 | Progress toward in vivo use of siRNAs-II |
| Q24634231 | Pseudovirions as vehicles for the delivery of siRNA |
| Q37736499 | RNA interference therapy for glioblastoma |
| Q37678411 | RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? |
| Q55360697 | RNA interference: new mechanistic and biochemical insights with application in oral cancer therapy. |
| Q47587577 | RNAi nanoparticles in the service of personalized medicine. |
| Q38541950 | RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies |
| Q37866632 | RNAi-based therapeutic strategies for metabolic disease |
| Q34659612 | RNAi-based therapeutics-current status, challenges and prospects |
| Q37665303 | Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application |
| Q28396399 | Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA |
| Q47567258 | Resurrecting DNAzymes as sequence-specific therapeutics |
| Q38096156 | Safety assessment of food and feed from biotechnology-derived crops employing RNA-mediated gene regulation to achieve desired traits: a scientific review. |
| Q37326825 | Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model |
| Q33486742 | Sequence determinants of innate immune activation by short interfering RNAs. |
| Q33566425 | Sequence-non-specific effects of RNA interference triggers and microRNA regulators |
| Q29039090 | Silencing disease genes in the laboratory and the clinic |
| Q38017713 | Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers |
| Q37950261 | Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. |
| Q34020246 | Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing |
| Q104073810 | Synthesis and use of an amphiphilic dendrimer for siRNA delivery into primary immune cells |
| Q37469987 | Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. |
| Q46041681 | TLR8 activation and inhibition by guanosine analogs in RNA: Importance of functional groups and chain length |
| Q28087657 | Technologies for controlled, local delivery of siRNA |
| Q38885511 | Therapeutic Potentials of Noncoding RNAs: Targeted Delivery of ncRNAs in Cancer Cells |
| Q52711221 | Worth the RISC? |
| Q92734224 | miRNAs as Influencers of Cell-Cell Communication in Tumor Microenvironment |
| Q27026234 | siRNA Delivery from an Injectable Scaffold for Wound Therapy |
| Q35261103 | siRNA for Influenza Therapy |
| Q33454280 | siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model. |
| Q38074462 | siRNA therapeutics in the treatment of diseases. |
Search more.